No Data
Chinese Drug Regulator Accepts Huahai Pharma Unit's Application for Adalimumab Injection
Huahai Pharmaceutical's Two Drugs Secures Spot in China's National Drug Procurement Program
Zhejiang Huahai Pharmaceutical (600521.SH): Products are expected to be selected for the tenth batch of national pharmaceutical centralized procurement.
On December 13, Gelonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that on December 12, 2024, the company participated in the bidding for the 10th batch of national drug centralized procurement organized by the National Joint Procurement Office, and the company products Apsaglerone Tablets and Sitagliptin Metformin Tablets (II) are expected to be selected for this centralized procurement.
Zhejiang Huahai Pharmaceutical (600521.SH): The application for the marketing authorization of adalimumab injection has been accepted.
Zhejiang Huahai Pharmaceutical (600521.SH) announced that its wholly-owned subsidiary Zhejiang Huahai Biotechnology Co., Ltd...
Zhejiang Huahai Pharmaceutical Gets China Nod for Type 2 Diabetes Drug
Zhejiang Huahai Pharmaceutical (600521.SH): Metformin and Ertugliflozin Tablets (I) have obtained the Pharmaceutical registration certificate.
On December 10, Guolonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced it has recently received the "Drug Registration Certificate" for Metformin and Empagliflozin Tablets (I) issued by the National Medical Products Administration. The approved product is intended to be used in conjunction with dietary control and exercise for adult patients with type 2 diabetes who are undergoing treatment with Empagliflozin and Metformin hydrochloride, aimed at improving blood sugar control in these patients.
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects
